Opthea Spon American Depositary Receipts Representing 8 Ord Shs OPT

Alternate Symbol(s): CKDXF

Healthcare Biotechnology

Opthea Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is engaged in developing novel therapies to address the unmet need in the treatment of prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate, sozinibercept (OPT-302), is being evaluated in two pivotal Phase 3 clinical trials for use in combination with standard-of-care anti-VEGF-A monotherapies for the treatment of wet AMD and DME. The Company has also manufactured OPT-302 for use in Phase III clinical trials, conducts activities to support the commercialization of the product and expanded its management team in the United States to facilitate broader oversight and execution of its Phase III program. Its development activities are based on an intellectual property portfolio covering key targets (Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3).

NDAQ:OPT - Post by User

Opthea Spon American Depositary Receipts Representing 8 Ord Shs

Bullboard Posts

Next >>

(303)
•••

Post by whytestockson Nov 15, 2024 7:00pm

31 Views

Post# 36315941

Opthea Appoints Kathy Connell to Board of Directors

JUST IN: $OPT Opthea Appoints Kathy Connell to Board of DirectorsMs. Connell is a commercial executive with business development expertise Appointment takes place as Opthea prepares for Phase 3 wet AMD topline data in 2025 MELBOURNE, Australia, and PRINCETON, N.J., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea&...OPT - Opthea Appoints Kathy Connell to Board of Directors

Bullboard Posts

Next >>

Cizzle Brands, Changing Consumer Habits in Consumables